AcuamarkDx Welcomes New Board Members
NEW YORK--Acuamark Diagnostics (AcuamarkDx), a forward-thinking company focused on early cancer detection technology, has proudly announced the onboarding of two highly experienced individuals, Tim Gordon and Chiara Gabbi, MD, PhD, to its board of directors.
AcuamarkDx expressed enthusiasm in welcoming these accomplished professionals. Bernard Peperstraete, MD, Co-Founder & CEO, noted, "Their diverse expertise in financial strategy and clinical research will significantly enrich the board as we progress with our technology development and transition towards commercialization. Tim has a remarkable track record in leading companies through financial milestones, while Chiara offers an invaluable scientific perspective."
Meet the New Board Members
Tim Gordon introduces a wealth of experience, spanning over 40 years at Ernst & Young. His extensive background includes audit and financial advisory roles in both US and international health and life sciences sectors. Gordon has successfully guided numerous companies through critical phases, including IPOs and mergers. His academic credentials include completing the Advanced Management Program at Harvard Business School. Additionally, he holds both UK Chartered Accountant and US CPA designations.
On the other hand, Dr. Chiara Gabbi is recognized as an innovative physician-scientist, boasting 20 years in clinical and translational medicine. Her work spans metabolic diseases, cancer, and personalized medicine, leading large, multicenter trials. With a PhD in medical science from Karolinska Institutet and an MD in Internal Medicine from the University of Modena and Reggio Emilia, Dr. Gabbi also holds a certificate in clinical research from Harvard Medical School.
AcuamarkDx’s Advancements in Cancer Detection
AcuamarkDx specializes in developing cutting-edge qPCR and methylation-based diagnostic technologies aimed at detecting early cancer signals with remarkable accuracy from blood samples. Recent clinical findings demonstrate that their top-performing models achieved an impressive 92% sensitivity and 97% specificity across colorectal cancer stages 1-4, with a publication forthcoming. The company has successfully raised around $25 million to fuel its ongoing Series B fundraising efforts, aimed at accelerating clinical developments, particularly in colorectal cancer.
Gordon shared his excitement about joining AcuamarkDx at a transformative phase, stating, "Acuamark has built a sophisticated technology that can enable accessible and precise early cancer detection for everyone. Following the company's journey as an early investor, I am continually impressed by the caliber of the team and the robustness of its business model."
Dr. Gabbi echoed this sentiment, expressing her eagerness to contribute to the mission of revolutionizing early cancer detection in clinical practice, emphasizing the technology's potential impact on patient survival and the economic burden on healthcare systems.
About Acuamark Diagnostics Inc.
Acuamark Diagnostics, Inc. stands at the forefront of molecular diagnostics. They are dedicated to creating an innovative, ultra-sensitive, and automatable technology that enhances the reliability and cost-effectiveness of early cancer detection. Their blood-based assays aim to solve the traditional diagnostic trade-offs by providing results that merge high sensitivity with specificity, setting a new standard for sequential cancer monitoring within primary care. By shifting treatment to earlier disease stages, AcuamarkDx aspires to enhance patient outcomes, mitigate the costs associated with late-stage cancer detection, and promote a more equitable healthcare model.
Frequently Asked Questions
What is AcuamarkDx known for?
AcuamarkDx specializes in developing early cancer detection technologies that focus on accurate diagnostics from blood samples.
Who are the new board members of AcuamarkDx?
The newly appointed board members are Tim Gordon and Chiara Gabbi, MD, PhD, both bringing extensive experience in finance and clinical research.
What is the significance of their recent board appointments?
Their appointments reflect AcuamarkDx's commitment to enhancing its leadership to advance cancer detection technologies and achieve commercialization.
How does AcuamarkDx's technology work?
The company utilizes advanced qPCR and methylation-based technology to detect early cancer signals in blood samples with high accuracy.
What is AcuamarkDx's goal in cancer detection?
AcuamarkDx aims to enable earlier detection and better treatment outcomes for cancer patients through innovative diagnostic solutions.
